Active Tissue Factor Pathway Inhibitor (TFPI) Homo sapiens (Human) Active protein

TFI; EPI; LACI; TFPI1; Lipoprotein-Associated Coagulation Inhibitor; Extrinsic pathway inhibitor

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point5.7
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Tissue Factor Pathway Inhibitor (TFPI) Packages (Simulation)
  • Active Tissue Factor Pathway Inhibitor (TFPI) Packages (Simulation)
  • APA394Hu03.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Human TFPI, also known as lipoprotein-associated coagulation inhibitor (LACI) and extrinsic pathway inhibitor (EPI), is a physiological inhibitor of extrinsic pathway of coagulation and has biological functions of anticoagulation and anti-inflammation. It is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C-terminal basic region. The activity of recombinant human TFPI was measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate Mca-RPKPVE-Nval-WRK(Dnp)-NH2 in the assay buffer 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5. Trypsin was diluted to 50 ug/ml in the assay buffer and 20 ul different concentrations of recombinant human TFPI (MW: 55.58 KD) was incubated with 20 ul diluted trypsin at 37 ℃ for 15 minutes. Loading 50 µL of the incubated mixtures which were diluted five-fold in assay buffer into empty wells of a plate, and start the reaction by adding 50 µL of 20 µM substrate. Include a substrate blank containing 50 µL of assay buffer and 50 µL of 20 µM substrate. Then read at excitiation and emission wavelengths of 320 nm and 405 nm, respectively, in kinetic mode for 5 minutes. The result was shown in Figure 1 and it was obvious that recombinant human TFPI significantly decreased trypsin activity. The inhibition IC50 was <17 nM.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Tissue factor pathway inhibitor in paediatric patients with nephrotic syndromeSajch: 383
  • Cathepsin G in Experimental Tuberculosis: Relevance for Antibacterial Protection and Potential for ImmunotherapyPubMed: 26320257
  • Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptorsPubMed: 25546502
  • Endothelial cell‐anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in micePubMed: 25945811
  • Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect ofLMWH tinzaparin.pubmed:27435911
  • Kunitz-type protease inhibitor as a vaccine candidate against schistosomiasis mansonipubmed:29128645

Recommend products